Assess whether the primary endpoint will survive FDA scrutiny from 505(b)(2)

SITUATION FDA Response and Labeling work in a safety team sitting on a new disproportionate signal now turns on the primary endpoint will because a boxed-warning proposal from the review division put 505(b)(2) literature-to-product bridge table in play. Pharmacovigilance medical reviewer should say what 505(b)(2) literature-to-product bridge table proves.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a boxed-warning proposal from the review division for pharmacovigilance medical reviewer. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision the primary endpoint will turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a boxed-warning proposal from the review division and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - FDA Response and Labeling finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform - Missing page in 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division, if any